Twenty-two patients (7%) received an FLT3 TKI associated with the first induction course: four patients (1.3%) received quizartinib in the QUANTUM-FIRST clinical trial (NCT02668653), and 18 (5.7%) received ponatinib in the PONATINIB-AML clinical trial (NCT02428543). The gene discussed is FLT3; the disease is acute myeloid leukemia.